On 16th October’14, BrilliantPennyStocks.com initiated coverage on COCP. The stock moved up by 47.88% since the coverage was initiated.
Biotechnology firm Cocrystal Pharma, Inc. (OTCMKTS:COCP) announced recently that it had developed a unique “high-throughput screening technology” designed to identify a key inhibitor which is linked to the dreaded Ebola virus gene. The announcement came in the third week of October, when World Health Organization had disclosed that the number of Ebola virus infected patients globally had officially crossed the 10000 mark.
Internally Developed Tech Platform
Cocrystal Pharma, Inc. (OTCMKTS:COCP) Chief Scientist, Dr. Roger Kornberg disclosed that the unique test has been developed by using the technology platform which has been created indigenously by the firm’s researchers.
Scientist Explains Modus Operando
Dr. Kornberg goes on to explain that, "We are very excited to have cloned the gene, purified and characterized its product, and integrated the gene product into our high-throughput platform. We believe we are the first group to have developed a novel screening methodology that can accurately identify inhibitors, which are potential drug candidates."
Investor Interest In The Stock Peaked
The announcement of this breakthrough tests is expected to buoy the prospects of the stock over the next few quarters. Prior to this announcement, Cocrystal Pharma, Inc. (OTCMKTS:COCP) had shared as part of its 2Q14 results announcement, the progress it has achieved with respect to its other drug development programs.
Other Key Drug Development Updates
On the earnings call, it had reported that Hepatitis C drug “CDI-244” development program continued at an even pace. It had indicated that it would be initiating clinical trials for this drug candidate by early next year.
The drug firm had also expressed satisfaction at the pace of development of its inhibitors designed to “stall the infection of influenza end nuclease.
The drug maker has indicated that its inhibitors are likely to offer greater resistance against the virus transmitters in comparison to existing treatments. Clinical studies for this are expected to commence in December 2015.
Signup now to receive the next BPS alert by clicking HERE
About BrilliantPennyStocks
BSP provides sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. BPS provides alerts to investors and traders on stocks that could potentially breakout. To obtain text message stock alerts service, text the word Avauncer to 95577 from your cell phone. Additionally, BPS provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.
Disclosure: BrilliantPennyStocks is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://brilliantpennystocks.com/disclaimer/ for complete risks and disclosures.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
